Ekkerhard Schillinger

Title: The Innovative Contributions of Ekkerhard Schillinger

Introduction

Ekkerhard Schillinger is a notable inventor based in Berlin, Germany. He has made significant strides in the field of male contraception, particularly through his innovative patent. His work focuses on developing formulations that effectively suppress spermatogenesis in males.

Latest Patents

Schillinger holds a patent for a male contraceptive formulation comprising norethisterone. This formulation utilizes a progestin that possesses both estrogenic and androgenic properties, making it remarkably effective for spermatogenesis suppression. The progestin Norethisterone (NET), along with its derivatives such as Norethisterone acetate and Norethisterone enanthate, can induce oligozoospermia or azoospermia in males when administered in sufficient doses. Additionally, the formulation can include an androgen, such as a testosterone derivative, particularly testosterone undecanoate, which enhances its effectiveness as a male contraceptive.

Career Highlights

Schillinger's career is marked by his dedication to advancing male contraceptive options. His innovative approach has opened new avenues for research and development in this critical area of reproductive health. He is associated with Schering Aktiengesellschaft, a company known for its contributions to pharmaceuticals and healthcare.

Collaborations

Schillinger has collaborated with esteemed colleagues in his field, including Eberhard Nieschlag and Axel Kamischke. Their combined expertise has furthered the research and development of male contraceptive methods.

Conclusion

Ekkerhard Schillinger's contributions to male contraception through his innovative patent highlight the potential for new reproductive health solutions. His work continues to influence the field and offers hope for effective male contraceptive options in the future.